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Abstract 
Background: Various complications lead to reoperation in patients who undergo prosthetic valve replacement 
where inflammatory process could be involved. The goals of this study were to identify risk factors that correlate with 
reoperation in patients with prosthetic heart valves and to investigate the relationship between reoperation and 
inflammatory gene polymorphisms.
Results: The study included 228 patients from the EwhA–Severance Treatment Group of Warfarin. Single nucleotide 
polymorphisms of c-reactive protein (CRP), interferon-gamma, interleukin 1 beta, interleukin 6, interleukin 10, trans-
forming growth factor beta 1, and tumor necrosis factor genes were genotyped by means of SNaPshot and TaqMan 
assays. Thirty-nine patients (17.1 %) underwent more than one heart valve operation. A threefold increased risk for 
heart valve reoperation was evident in homozygous variant-type (TT) carriers as compared with ancestral allele car-
riers of CRP rs1205. Logistic regression analysis revealed that CRP rs1205 (OR 2.68, 95 % CI 1.22–5.90, p = 0.014), valve 
position (mitral valve OR 2.80, 95 % CI 1.01–7.80, p = 0.048; tricuspid valve OR 9.24, 95 % CI 2.46–34.70, p = 0.001; 
reference: aortic valve) and time after first operation (OR 1.13, 95 % CI 1.06–1.20, p < 0.001) affected the risk of 
reoperation.
Conclusions: Inflammatory gene polymorphisms could be a possible marker of risk for reoperation in patients with 
prosthetic heart valve surgery.
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Background
Currently, approximately 280,000 prosthetic heart valves 
are implanted worldwide every year. Of these, about 
50  % are mechanical valves (Pibarot and Dumesnil 
2009). However, prosthetic heart valves may require one 
or more reoperations. About 10  % of the patients with 
an aortic or mitral mechanical valve usually undergo 
reoperation 10  years after the initial surgical procedure 
(Frank et  al. 1995). Reoperations are more complicated 
than the initial valve operations, and are associated with 
higher mortality rates with mechanical valves than with 
tissue valves (Jones et al. 2001).
Various complications lead to reoperation in patients 
who undergo prosthetic valve replacement, the most 
frequent being obstructive valve thrombosis and pan-
nus development (Rizzoli et  al. 1999). Valve thrombosis 
occurs when a thrombus is attached to or is near a pros-
thetic heart valve, obstructing blood flow or causing valve 
regurgitation. Other reasons for reoperation include fail-
ure of previous valve repair, paravalvular leakage, infec-
tive or non-infective endocarditis, and prosthetic valve 
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dysfunction due to fibrous tissue ingrowth and calcifica-
tion (Piehler et al. 1995).
The infiltration of activated macrophages and T-cells, 
as well as cytokine release, has been described in human 
stenotic aortic valves. Previous studies have shown that 
cardiac valve calcification and ossification also involve an 
inflammatory process. This process includes the release 
of cytokines, chemokines, growth factors, and hydrolytic 
enzymes that contribute to angiogenesis, atherosclerotic 
plaque growth, and ossification of the valve (Helske et al. 
2007). Although inflammation is assumed to be a factor 
in the occurrence of adverse complications after heart 
valve replacement (Sinning et al. 2012), studies to address 
the role of inflammatory gene polymorphisms related to 
valve surgery have been scarce. Therefore, this study was 
designed to determine the risk factors associated with 
reoperation in patients with prosthetic heart valves, with 
an emphasis on cytokine genetic polymorphisms, consid-




The study population consisted of 228 patients from the 
EwhA–Severance Treatment (EAST) Group of Warfa-
rin who underwent mechanical heart valve replacement 
between January 1982 and December 2009 at Severance 
Cardiovascular Hospital of Yonsei University College of 
Medicine in Seoul, Korea. EAST cohort is comprised of 
patients who had warfarin therapy after a mechanical 
heart valve replacement, and who did not have any evi-
dence of hepatic or renal impairment. Patients were fol-
lowed up continuously at the Severance Cardiovascular 
Hospital of Yonsei University Medical Center outpatient 
clinic. We reviewed the patients’ paper charts and elec-
tronic medical records from June 1983 through May 2013 
and collected data on age, age at the time of operation, 
gender, time after the first heart valve surgery, position 
of the valve prosthesis, INR, and comorbidities. Blood 
samples used for genotyping were collected from the 228 
patients during regular outpatient clinic visits. The study 
protocol was approved by the institutional review board 
and Ethics Committee of Severance Hospital (IRB No. 
2009-4-0283), and informed consent was obtained from 
all patients prior to their participation in the study.
Genotyping
Genomic DNA of study patients was prepared from 
ethylenediaminetetraacetic acid blood samples using 
a QIAamp DNA Blood Mini Kit (Qiagen, Hilden, 
Germany) according to standard procedures recom-
mended by the manufacturer. We selected single nucle-
otide polymorphisms of C-reactive protein (CRP), 
interferon-gamma (IFNG), interleukin-1beta (IL1B), 
interleukin-6 (IL6), interleukin-10 (IL10), transforming 
growth factor beta-1 (TGFB1), and tumor necrosis fac-
tor (TNFA) based on previously published data regarding 
genetic polymorphisms in inflammation-related diseases, 
including coronary artery disease and myocardial infarc-
tion (Table  1; Cruz et  al. 2013; Wang et  al. 2015; Garg 
et  al. 2013; Iacoviello et  al. 2005). Genotyping was con-
ducted using SNaPshot or TaqMan assays.
Statistical analyses
Univariate and multivariate analyses were performed to 
determine the association of these genotypes with the 
recurrence of heart valve operations. The Chi square test 
was used to compare categorical variables; if the expected 
frequencies were less than 5 in any one cell, we used Fish-
er’s exact test to obtain a p value. For continuous vari-
ables, an independent sample t test was performed, and 
their approximation to normality was judged by means of 
the Shapiro–Wilk W test. Depending on the distribution, 
either the t test or the Mann–Whitney test was used for 
analysis of the variables. A logistic regression model was 
used to investigate the factors that independently affected 
the number of operations. All analyses were performed 
with the SPSS Statistics version 20 software (IBM, New 
York City, NY, USA). Differences with a p value of less 
than 0.05 were considered statistically significant.
Results
A total of 228 patients who had undergone heart valve 
replacements were followed-up from June 1983 to May 
2013. Of these patients, 39 (17.1  %) underwent more 
than one heart valve operation. The reasons for reopera-
tions were failure of the previous repair (n =  14), valve 
dysfunction (n =  17), periprosthetic leak (n =  5), valve 
thrombosis (n = 1), endocarditis (n = 1), and unknown 
(n =  1). There was a significant difference between the 
patients with and those without reoperation in the aver-
age length of time after the first surgery (p < 0.001). More 
female than male patients had undergone reoperation 
(20.8 vs. 10.1 %, p =  0.042). Valve positions were a sta-
tistically significant predictor of reoperation, and tricus-
pid valve surgery posed the highest risk for reoperation. 
There were no significant differences between patients 
with and those without reoperation in terms of age, age 
at operation, percentage of time in the therapeutic range 
on warfarin, and comorbidities. Table 2 shows the demo-
graphic characteristics with regard to the number of 
heart valve operations.
We evaluated the effects on reoperation of eight genetic 
variants of seven inflammatory mediator genes in 228 
study patients. These genotypes included IL1B rs16944, 
IL6 rs1800796, IL10 rs1800871, IL10 rs1800896, IFNG 
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rs2430561, TNFA rs1800629, TGFB1 rs1800470, and 
CRP rs1205. The observed genotype frequencies were 
consistent with the Hardy–Weinberg equilibrium for 
all SNPs. A statistically significant association between 
genotypes and reoperation was found for IL10 rs1800896 
and CRP rs1205. We observed a 3.3-fold increased risk 
for reoperation of the heart valve in homozygous variant-
type (TT) carriers as compared with ancestral carriers of 
CRP rs1205. Two patients who carried CC allele of IL10 
rs1800896 underwent reoperation, but there were no CC 
allele carriers in the single operation group. In contrast, 
20.8  % of patients who carried the T allele underwent 
reoperation. Table 3 shows the association between reop-
eration and the grouped genotypes.
After adjustment for variables that were statistically 
significant on the univariate analyses (i.e., gender, time 
after first operation, body mass index, valve position, and 
CRP rs1205), the binary logistic regression analysis con-
firmed that time after first operation, valve position, and 
CRP rs1205 were significantly associated with reopera-
tion (Table 4). Patients with tricuspid valve replacements 
were at 9.2-fold increased risk for reoperation, compared 
with those who underwent aortic valve replacements. 
Variant-type homozygote carriers of CRP rs1205 showed 
a statistically higher risk for reoperation than did the 
ancestral allele carriers (p  =  0.014, adjusted OR 2.684, 
95 % CI 1.222–5.895).
Clinical characteristics of minor allele (TT) carriers of 
rs1205 were 55 females (66.3 %, p =  0.598), younger age 
groups (<65 years; 57.8 %, p = 0.466), mitral valve prosthe-
sis (50.6 %), and with atrial fibrillation (61.4 %, p = 0.070). 
However, rs1205 variant was not significantly associated 
with clinical demographics except for reoperation.
Subgroup analyses were conducted to compare the 
reoperation rate in relation to the genotypes in patients 
who underwent mitral valve operations. The first heart 
valve operation in 113 patients involved the mitral valve, 
and 23 of these patients underwent reoperation. The 
presence of TGFB1 rs1800470 and CRP rs1205 polymor-
phisms was statistically significant with respect to mitral 
valve reoperations (p  =  0.043 and p  =  0.031, respec-
tively). In addition, patients with the variant-type allele 
(A) of TGFB1 rs1800470 were at lower risk for reopera-
tion compared with those who had ancestral homozy-
gous alleles (G) (OR 0.377, 95 % CI 0.144–0.987; Table 5). 
Consistent with the whole-population analysis, the risk 
of reoperation was increased in the TT carriers of CRP 
rs1205 (OR 2.734, 95 % CI 1.073–6.969).




Gene rs number Global minor allele frequency Functional consequence Direction Primer sequence
IL1B rs16944 G = 0.4906 Upstream variant 2 KB Fa CCAGCCAAGAAAGGTCAAT
Rb GAAGAGGTTTGGTATCTGCCA
Gc CAATTGACAGAGAGCTCC
IL10 rs1800871 A = 0.4347 Upstream variant 2 KB F GAAACCAAATTCTCAGTTGGC
R ATGACCCCTACCGTCTCTATTT
G TGGTGTACCCTTGTACAGGTGATGTAA
IL10 rs1800896 C = 0.2722 Intron variant F ACACACACACAAATCCAAG
R ATAGGAGGTCCCTTACTTTCCTC
G TCCTCTTACCTATCCCTACTTCCCC
IFNG rs2430561 A = 0.2802 Intron variant F ATATTCAGACATTCACAATTGATT
R TATTATACGAGCTTTAAAAGATAGTTCC
G TTTATXCTTACAACACAAAATCAAATC
TNFA rs1800629 A = 0.0903 Upstream variant 2 KB F AGAAGGAAACAGACCACAGAC
R GGGAAAGAATCATTCAACCA
G TAGGTTTTGAGGGGCATG
TGFB1 rs1800470 G = 0.4547 Missense F GCCCATCTAGGTTATTTCC 
R TGCCAGTCACTTCCTACC 
G AGCAGCGGTAGCAGCAGC 
CRP rs1205 T = 0.3383 UTR variant 3 prime F ATCTTYTTGCTGCTGGATTTC
R TTGTTTGTCAATCCCTTGG
G CTTGTTTGCCACATGGWGAGAGACT
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Discussion
Advances in surgical techniques and progress in valve 
design and materials have improved the clinical out-
comes of patients with heart valve diseases. However, the 
placement of prosthetic heart valves often requires one or 
more reoperations. Several studies have sought to iden-
tify factors related to the occurrence of prosthetic valve 
dysfunction. Although the main causes may vary with 
patient demographic characteristics, disease progression 
as well as prosthesis type, model, and implantation sites 
were found to be influential factors (Aydin and Yapici 
2013; Weerasinghe et al. 1999; Chan et al. 2011). In this 
study, we focused on genetic risk factors to investigate 
the association of gene polymorphisms of inflammatory 
mediators with reoperation after prosthetic heart valve 
placement.
As has been noted by previous researchers, time after 
the initial operation also affected the risk of reoperation 
in our study patients (Rahimtoola 2010; Khan et al. 2001). 
In addition, based on the results of our univariate analy-
sis, gender, body mass index, and valve position were 
found to correlate with the risk for reoperation.
Conflicting results have been reported regarding the 
effect of gender on the risk of valve surgery (Lytle et al. 
Table 2 Demographic characteristics and number of heart 
valve operations
a Aortic plus mitral valve
b Any valve replacements including tricuspid valve
Characteristics Patient number or 
mean ± SD
p value




Time after first operation (years) 16 ± 7 23 ± 9 0.002
Age 58 ± 10 57 ± 10 0.333
Age at first operation 43 ± 11 45 ± 11 0.476
Gender
 Male 71 8 0.042
 Female 118 31
Body mass index (kg/m2) 22.84 ± 2.77 21.70 ± 2.99 0.023
Time in therapeutic range on warfarin
 <60 % 132 27 0.866
 ≥60 % 55 12
Valve position
 Aortic 52 5 0.001
 Mitral 90 23
 Doublea 38 3
 Tricuspidb 9 8
Comorbidity
 Hypertension
  Absent 139 30 0.661
  Present 50 9
 Diabetes mellitus
  Absent 174 34 0.326
  Present 15 5
 Congestive heart failure
  Absent 146 34 0.166
  Present 43 5
 Atrial fibrillation
  Absent 85 13 0.181
  Present 104 26
 Myocardial infarction
  Absent 84 17 1.000
  Present 105 22
Table 3 Association between  reoperation and  grouped 
genotypes of inflammatory mediators
OR odds ratio, CI confidence interval, IL1B interleukin-1beta, IL6 interleukin-6, 
IL10 interleukin-10, INFG interferon-gamma, TNFA: tumor necrosis factor alpha, 
TGFB1: transforming growth factor-beta1, CRP: C-reactive protein











 AA, AG 126 27 0.756 1
 GG 63 12 0.889 (0.422–1.871)
IL6 rs1800796 (0.27)
 GG 15 2 0.744 1
 GC, CC 172 37 1.613 (0.534–7.359)
IL10 rs1800871 (0.29)
 AA, AG 170 37 0.743 1
 GG 15 2 0.613 (0.134–2.794)
IL10 rs1800896 (0.07)a
 TT, TC 184 37 0.030
 CC 0 2
IFNG rs2430561 (0.20)
 AA 154 31 0.574 1
 AT, TT 31 8 1.282 (0.538–3.053)
TNFA rs1800629 (0.04)
 GG 173 37 0.548 1
 GA, AA 16 2 0.584 (0.129–2.652)
TGFB1 rs1800470 (0.47)
 GG, GA 145 29 0.584 1
 AA 40 10 1.250 (0.562–2.780)
CRP rs1205 (0.40)
 CC, CT 129 15 0.001 1
 TT 60 23 3.297 (1.606–6.766)
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1986; Cohn et al. 1993). However, it is known that man-
agement and outcomes of valvular surgery can differ 
between men and women owing to differences in patho-
physiology and body size (Redberg and Schiller 2004).
Consistent with previous findings, valve position 
affected risk of reoperation, showing highest risk in tri-
cuspid valve replacement possibly because of the rela-
tively high incidence of thrombosis or pannus ingrowth 
(Jones et al. 2001).
Although body weight has been shown to be associ-
ated with inflammation in previous studies, we found the 
reverse trend in our study (Fogarty et al. 2008; Nicklas et al. 
2004). Obesity was not found to be a risk factor for adverse 
outcomes after valve surgery in other studies; however, 
our study confirmed that body mass index was associated 
with reoperation when analyzed as a continuous variable 
(p = 0.023) but not as a categorical variable using a cutoff 
of 25 kg/m2 (p = 0.069) (Allama et al. 2013). An absolute 
comparison cannot be made between our results and pre-
vious studies because the average body mass index of our 
patients in both groups was within normal range (20.0–
24.9 kg/m2) and was rather lower on average in our study 
group as a whole (mean = 22.7 ± 2.8 kg/m2).
Insufficient anticoagulation or fluctuations in INR val-
ues within the therapeutic range can cause obstructive 
valve dysfunction. Therefore, we evaluated the effects of 
time to therapeutic range on the need for reoperation. 
A TTR cutoff value of 60  % was used based on previ-
ous studies in which patients with a TTR below 55–60 % 
had higher mortality and a higher incidence of bleeding 
(White et al. 2007). However, our results did not indicate 
that TTR was a predictor of reoperation (p = 0.866).
One of the main observations in this study was that 
reoperation was associated with inflammatory gene poly-
morphisms. Among the inflammatory mediators, CRP 
rs1205 was found to be associated with reoperation based 
on our final logistic regression model. Although SNPs of 
the other inflammatory mediator genes we tested were 
not statistically significant, we cannot exclude other 
genes from among the risk factors for reoperation, 
because allele frequencies can vary among ethnic groups, 
thus contributing to differences in outcomes.
Following the implantation of foreign material, acute 
and chronic inflammation can occur due to mediators 
such as interleukins, histamines, and growth factors. 
Moreover, inflammatory responses may affect the dura-
bility of prosthetic valves because thrombosis and deg-
radation often occur in response to the activation and 
aggregation of platelets and inflammatory cells (Alavi 
et  al. 2013). Many ongoing studies have explored the 
association between CRP genetic polymorphisms and 
Table 4 Results of logistic regression analysis
The odds ratio was adjusted for gender, time after first operation, body mass 
index, valve position, and CRP rs1205




 Male 1 0.179
 Female 1.970 (0.732–5.303)
Time after first operation 
(year)
1.129 (1.063–1.199) <0.001
Body mass index (kg/m2) 0.911 (0.765–1.086) 0.300
Valve position
 Aortic 1
 Mitral 2.804 (1.009–7.796) 0.048
 Double 0.821 (0.185–3.648) 0.796
 Tricuspid 9.244 (2.463–34.695) 0.001
CRP rs1205
 CC, CT 1 0.014
 TT 2.684 (1.222–5.895)
Table 5 Subgroup analysis of  patients with  mitral valve 
operation
a Odds ratio was not calculated due to no patients in certain group
Gene polymor-
phisms (minor allele 
frequency)





 AA, AG 65 15 0.510 1
 GG 25 8 1.387 (0.523–3.673)
IL6 rs1800796 (0.26)
 GG 22 1 0.692 1
 GC, CC 83 7 1.855 (0.217–15.886)
IL10 rs1800871 (0.27)
 AA, AG 79 22 0.466 1
 GG 9 1 0.399 (0.048–3.332)
IL10 rs1800896 (0.06)a
 TT, TC 88 23 0.205
 CC 0 1
IFNG rs2430561 (0.08)
 AA 76 20 1.000 1
 AT, TT 13 3 0.877 (0.228–3.378)
TNFA rs1800629 (0.04)
 GG 80 23 0.471 1
 GA, AA 9 1 0.409 (0.049–3.405)
TGFB1 rs1800470 (0.46)
 GG, GA 20 10 0.043 1
 AA 69 13 0.377 (0.144–0.987)
CRP rs1205 (0.40)
 CC, CT 61 10 0.031 1
 TT 29 13 2.734 (1.073–6.969)
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their contribution to disease risk. One study found that 
the minor allele of the rs1205 CRP polymorphism could 
serve as a potential marker in identifying subjects prone 
to severe and heavily calcified aortic stenosis (Wypasek 
et  al. 2015). Another study found that rs1205 was asso-
ciated with a decreased risk of cardiovascular mortality 
in Caucasians (Lange et  al. 2006). On the other hand, a 
huge randomization meta-analysis conducted by Wens-
ley and colleagues showed that CRP levels genetically 
determined by CRP polymorphisms including rs1205 
are unrelated to risk for coronary heart disease (Wens-
ley et al. 2011). These conflicting results are not surpris-
ing, because just as the distribution of CRP alleles differs 
among races, disease risk also differs among races.
At present, the CRP rs1205 polymorphism is related 
to prosthetic valve dysfunction in Koreans patients who 
have undergone mechanical heart valve replacement, 
which presumably involves inflammatory responses. 
At this point, it is not easy to explain the mechanism 
underlying the observed association between the rs1205 
polymorphism and heart valve reoperation. Previous 
researches reported that CRP, a biomarker of inflamma-
tion, was associated with valve stenosis which involves 
calcification and activation of local and systemic inflam-
mation. CRP rs1205 mutation was associated with 
elevated CRP levels in patients with valve stenosis, sug-
gesting inflammatory response and which can further be 
related with reoperation. Studies on the mechanism gov-
erning the contribution of rs1205 mutation to the need 
for reoperation remains to be determined.
The possible functionality of 3′-UTR rs1205 polymor-
phism affecting the reoperation could involve increased 
inflammatory cytokines. 3′-UTR mutations can affect 
mRNA stability of genes harboring them. The 3′-UTR of 
CRP is quite long suggesting its special regulatory impor-
tance. A mechanism involving mRNA stability would be 
the effect on microRNA binding sites as 3′-UTR could 
be the main target leading to a change of post-transcrip-
tional regulation of gene expression. Another possible 
option would be that rs1205 polymorphism influences 
CRP expression by its linkage disequilibrium with 
another functional genetic variant. The complex haplo-
typic relationships can functionally influence the effects 
of rs1205 mutation (Potaczek et  al. 2012; Russell et  al. 
2004; Di Marco et al. 2001).
In the analysis of the subgroup of patients with mitral 
valve operation, TGFB1 rs1800470 was found to be sta-
tistically significant (p  =  0.043). One study suggested 
that the TGFB1 T29C (rs1800470) gene polymorphism 
could be associated with the risk of restenosis after cor-
onary stent placement (Fragoso et  al. 2015). This allele 
was previously associated with the risk of silent myocar-
dial ischemia and acute coronary syndrome (Cruz et  al. 
2013; Syrris et al. 1998). Functional studies investigating 
the underlying mechanism revealed that the presence of 
the T allele produces a binding site for SF2/ASF proteins, 
which belong to the family of serine/arginine-rich (SR) 
proteins that regulate alternative splicing, suggesting that 
the TGFB1 T29C polymorphism could have a functional 
effect (Syrris et al. 1998; Sureau et al. 2001).
There are several limitations of this study. This is a 
retrospective study in a single center using a single eth-
nic group. Detailed inflammatory clinical phenotypes 
such as CRP levels or pathological findings could not be 
gathered.
Conclusions
In conclusion, this study is the first to demonstrate a rela-
tionship between inflammatory gene polymorphisms and 
heart valve reoperation. Genetic polymorphisms of CRP 
rs1205 and TGFB1 rs1800470 were found to be factors 
influencing the need for reoperation, indicating the value of 
inflammatory gene variants as a possible marker for reop-
eration in patients who undergo prosthetic heart valve sur-
gery. Given that this study was carried out at a single center 
and that the sample size was relatively small, our hypoth-
esis requires further independent validation in multi-center 
studies with larger sample sizes of diverse ethnic groups.
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